PDB27 A COST-UTILITY ANALYSIS OF ORLISTAT (XENICAL®) IN THE TREATMENT OF DIABETIC PATIENTS WITH MORBID OBESITY AND ADDITIONAL CVD RISK IN NORWAY
Nov 1, 2006, 00:00 AM
10.1016/S1098-3015(10)63297-4
https://www.valueinhealthjournal.com/article/S1098-3015(10)63297-4/fulltext
Section Title :
Section Order :
148
First Page :
https://www.valueinhealthjournal.com/action/showCitFormats?pii=S1098-3015(10)63297-4&doi=10.1016/S1098-3015(10)63297-4